Interestingly, DDR1 signaling has also been shown to enhance chemoresistance of breast cancer cells via NFκB-mediated expression of cyclooxygenase-2 (COX-2), and downregulation of DDR1 significantly enhanced drug sensitivity (Das et al., 2006). The gene discussed is PTGS2; the disease is breast cancer.